Invites Healthcare Co., Ltd. agreed to acquire a 20.03% stake in Biocore Co., Ltd. from Hongkong Dian Biotechnology Co., Limited for KRW 12 billion.
July 30, 2020
Share
Invites Healthcare Co., Ltd. agreed to acquire a 20.03% stake in Biocore Co., Ltd. (XKON:A216400) from Hongkong Dian Biotechnology Co., Limited for KRW 12 billion on July 1, 2020. Under the terms of the transaction, Invites Healthcare will acquire 1.38 million shares for KRW 8,650 per share. Upon completion of the transaction, Hongkong Dian Biotechnology will not hold any stake in Biocore. The transaction was approved by the Board of Directors of Dian Diagnostics Group, parent of Hongkong Dian Biotechnology.
Invites Biocore Co Ltd, formerly BioCore Co Ltd, is a Korea-based company mainly engaged in the provision of medical examination services. The Company operates its business through two segments. The New Drug Development Business segment is involved in the provision of bioequivalence testing, drug in vivo kinetics research, drug analysis in biological samples, toxicity kinetics testing, microanalysis in pharmaceuticals, comparative dissolution testing, and clinical trial consulting. The Biotechnology Business segment is engaged in the provision of customized genome analysis services and the manufacture and sale of diagnostic kits. The Companyâs products are sold under the brand of Bio-Core.
INVITES BIOCORE CO., LTD. 
